These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 37630254)
1. Modulation of NRF2/KEAP1-Mediated Oxidative Stress for Cancer Treatment by Natural Products Using Pharmacophore-Based Screening, Molecular Docking, and Molecular Dynamics Studies. Alzain AA; Mukhtar RM; Abdelmoniem N; Shoaib TH; Osman W; Alsulaimany M; Aljohani AKB; Almadani SA; Alsaadi BH; Althubyani MM; Mohamed SGA; Mohamed GA; Ibrahim SRM Molecules; 2023 Aug; 28(16):. PubMed ID: 37630254 [TBL] [Abstract][Full Text] [Related]
2. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex. Bello M; Morales-González JA Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889 [TBL] [Abstract][Full Text] [Related]
3. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques. Londhe AM; Gadhe CG; Lim SM; Pae AN Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716 [TBL] [Abstract][Full Text] [Related]
4. A computational study to identify Sesamol derivatives as NRF2 activator for protection against drug-induced liver injury (DILI). Mili A; Birangal S; Nandakumar K; Lobo R Mol Divers; 2024 Jun; 28(3):1709-1731. PubMed ID: 37392347 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking. Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289 [TBL] [Abstract][Full Text] [Related]
7. Molecular docking and dynamics guided approach to identify potential anti-inflammatory molecules as NRF2 activator to protect against drug-induced liver injury (DILI): a computational study. Mili A; Das S; Nandakumar K; Lobo R J Biomol Struct Dyn; 2023 Nov; 41(19):9193-9210. PubMed ID: 36326112 [TBL] [Abstract][Full Text] [Related]
8. Identification of potential andrographolide-based drug candidate against Keap1-Nrf2 pathway through rigorous cheminformatics screening. Jain P; Sudandira Doss C Mol Divers; 2023 Feb; 27(1):341-356. PubMed ID: 35467270 [TBL] [Abstract][Full Text] [Related]
9. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1). Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning. Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749 [TBL] [Abstract][Full Text] [Related]
11. Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish. Raghunath A; Nagarajan R; Sundarraj K; Palanisamy K; Perumal E Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):259-270. PubMed ID: 30861618 [TBL] [Abstract][Full Text] [Related]
12. Molecular docking and molecular dynamics simulation of wheat gluten-derived antioxidant peptides acting through the Keap1-Nrf2 pathway. Liu W; Liu R; Qin Q; Wang H; Zhang X; Meng G J Sci Food Agric; 2024 Oct; 104(13):8150-8161. PubMed ID: 38837798 [TBL] [Abstract][Full Text] [Related]
13. A bioactive ligand-conjugated iridium(III) metal-based complex as a Keap1-Nrf2 protein-protein interaction inhibitor against acetaminophen-induced acute liver injury. Li G; Liu H; Feng R; Kang TS; Wang W; Ko CN; Wong CY; Ye M; Ma DL; Wan JB; Leung CH Redox Biol; 2021 Dec; 48():102129. PubMed ID: 34526248 [TBL] [Abstract][Full Text] [Related]
14. Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations. Mohamed GA; Abdallah HM; Sindi IA; Ibrahim SRM; Alzain AA PLoS One; 2024; 19(8):e0308913. PubMed ID: 39163297 [TBL] [Abstract][Full Text] [Related]
15. Ginnalin A Binds to the Subpockets of Keap1 Kelch Domain To Activate the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells. Zhang Z; Peng L; Fu Y; Wang W; Wang P; Zhou F ACS Chem Neurosci; 2021 Mar; 12(5):872-882. PubMed ID: 33571414 [TBL] [Abstract][Full Text] [Related]
16. mPGES-1 Inhibitor Discovery Based on Computer-Aided Screening: Pharmacophore Models, Molecular Docking, ADMET, and MD Simulations. Huang Q; Lai T; Wang Q; Luo L Molecules; 2023 Aug; 28(16):. PubMed ID: 37630311 [TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions. Lu MC; Shao HL; Liu T; You QD; Jiang ZY Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756 [TBL] [Abstract][Full Text] [Related]
18. Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction. Begnini F; Geschwindner S; Johansson P; Wissler L; Lewis RJ; Danelius E; Luttens A; Matricon P; Carlsson J; Lenders S; König B; Friedel A; Sjö P; Schiesser S; Kihlberg J J Med Chem; 2022 Feb; 65(4):3473-3517. PubMed ID: 35108001 [TBL] [Abstract][Full Text] [Related]
19. Attenuation of Nrf2/Keap1/ARE in Alzheimer's Disease by Plant Secondary Metabolites: A Mechanistic Review. Fakhri S; Pesce M; Patruno A; Moradi SZ; Iranpanah A; Farzaei MH; Sobarzo-Sánchez E Molecules; 2020 Oct; 25(21):. PubMed ID: 33114450 [TBL] [Abstract][Full Text] [Related]
20. Screening of phytochemicals against Keap1- NRF2 interaction to reactivate NRF2 Functioning: Pharmacoinformatics based approach. Akmal A; Javaid A; Hussain R; Kanwal A; Zubair M; Ashfaq UA Pak J Pharm Sci; 2019 Nov; 32(6(Supplementary)):2823-2828. PubMed ID: 32024620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]